Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Endocrinology

Managing Recurrence: Your Roadmap for Next Steps

At a Glance

If Cushing disease returns after initial surgery, multiple effective treatments are available to normalize your cortisol levels. Management options include cortisol-blocking medications like osilodrostat, targeted pituitary radiation, or surgically removing the adrenal glands.

If surgery does not result in remission or if the disease returns later (recurrence), it can feel like a setback. However, modern medicine provides several “lines of defense” to manage Cushing disease. Your care team’s goal will shift from a single surgical fix to a management plan designed to bring your cortisol levels back into a safe, normal range [1][2].

Medication: Blocking the Factory or the Signal

When surgery is not enough, medications can be used to lower cortisol. These drugs generally work in one of two ways:

1. Blocking the “Factory” (Adrenal Glands)

These drugs, known as steroidogenesis inhibitors, stop the adrenal glands from producing cortisol, regardless of the signal coming from the brain.

  • Osilodrostat: This is a newer, highly effective medication. In clinical trials, up to 90% of patients achieved normal cortisol levels [3]. It works rapidly and has been shown to improve physical symptoms like high blood pressure and blood sugar [1][4].
  • Ketoconazole: A long-standing treatment that blocks several steps in cortisol production. It is effective but requires careful monitoring of liver function [5][6].

2. Blocking the “Signal” (Pituitary Tumor)

  • Pasireotide: This is a pituitary-targeted therapy. It works by binding to specific receptors (SSTR5) on the tumor itself to slow down ACTH production [7]. It is particularly useful for patients whose tumors have high levels of these receptors [8]. A common side effect to watch for is an increase in blood sugar [9].

Radiation: Precision Targeting

If a small piece of the tumor (the PitNET) remains or returns, stereotactic radiosurgery (SRS) can be used. This is not traditional “wide-beam” radiation; it is highly focused, aiming hundreds of tiny beams at the tumor with sub-millimeter precision [10].

  • Technologies: Common names for this include Gamma Knife, CyberKnife, or the newer ZAP-X platform [11].
  • The Wait: Unlike surgery, radiation does not work instantly. It can take 18 to 24 months—or even longer—to reach its full effect [12].
  • Long-term Monitoring: The main risk of radiation is hypopituitarism, where the radiation gradually affects the healthy parts of the pituitary gland over several years, requiring lifelong hormone replacement for other functions like thyroid or growth hormone [13][14].

Bilateral Adrenalectomy: The Final Option

In severe cases where surgery, radiation, and medications all fail, doctors may recommend a bilateral adrenalectomy (BLA). This involves surgically removing both adrenal glands [15][16].

  • The Result: This provides an immediate “cure” for high cortisol because the “factories” are gone [17].
  • The Trade-off: You will immediately enter a state of permanent adrenal insufficiency (Addison’s disease). You will need to take life-sustaining hormone replacement pills every day for the rest of your life [18].
  • Nelson’s Syndrome: Because the adrenal glands are gone, they no longer send “feedback” to the brain to slow down the pituitary tumor. In some patients, the original pituitary tumor can begin to grow rapidly after a BLA. This is called Nelson’s Syndrome, and it requires regular MRI monitoring [19][20].

Managing recurrent Cushing disease is often a multidisciplinary effort. While the journey may be longer than expected, the availability of high-efficacy drugs like osilodrostat and precision radiation means that hormone control is achievable for nearly every patient [21][22].

Common questions in this guide

What medications are used if Cushing disease comes back?
If Cushing disease returns, doctors may prescribe steroidogenesis inhibitors like osilodrostat or ketoconazole to block your adrenal glands from making cortisol. Alternatively, they may use pituitary-directed drugs like pasireotide to target the tumor directly and slow down its signals.
How long does radiation therapy take to work for Cushing disease?
Unlike surgery, highly focused radiation therapies such as Gamma Knife or CyberKnife do not lower cortisol levels instantly. It typically takes 18 to 24 months, or sometimes even longer, to reach its full effect in controlling the pituitary tumor.
What happens during a bilateral adrenalectomy?
A bilateral adrenalectomy is a surgery that removes both of your adrenal glands. This provides an immediate cure for high cortisol, but it causes permanent adrenal insufficiency, meaning you must take daily, life-sustaining hormone replacement pills for the rest of your life.
What is Nelson's syndrome?
Nelson's syndrome is a potential complication that can occur after a bilateral adrenalectomy. Without the adrenal glands sending feedback signals to the brain, the original pituitary tumor can begin to grow rapidly, which is why regular MRI monitoring is essential.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor’s pathology (like SSTR5 expression), would I be a good candidate for pasireotide?
  2. 2.If we start osilodrostat, how frequently will we monitor my potassium and cortisol levels to avoid adrenal insufficiency?
  3. 3.How long does it typically take for radiation (like Gamma Knife or ZAP-X) to fully control hormone levels?
  4. 4.If I undergo a bilateral adrenalectomy, what is my specific risk of developing Nelson’s syndrome, and how will we monitor for it?
  5. 5.What is the 'Plan B' if the first medication we try causes side effects or doesn't fully normalize my cortisol?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.

    Fleseriu M, Pivonello R, Lacroix A, et al.

    European journal of endocrinology 2025; (193(5)):606-617 doi:10.1093/ejendo/lvaf207.

    PMID: 41052284
  2. 2

    Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.

    Gadelha M, Snyder PJ, Witek P, et al.

    Frontiers in endocrinology 2023; (14()):1236465 doi:10.3389/fendo.2023.1236465.

    PMID: 37680892
  3. 3

    Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing's Disease in Spain.

    Araujo-Castro M, García-Centeno R, González L, et al.

    Journal of clinical medicine 2025; (14(21)) doi:10.3390/jcm14217575.

    PMID: 41226972
  4. 4

    Cushing's Disease: Long-Term Effectiveness and Safety of Osilodrostat in a Polish Group of Patients with Persistent Hypercortisolemia in the Experience of a Single Center.

    Dzialach L, Sobolewska J, Respondek W, et al.

    Biomedicines 2023; (11(12)) doi:10.3390/biomedicines11123227.

    PMID: 38137448
  5. 5

    Approach to the Patient Treated with Steroidogenesis Inhibitors.

    Castinetti F, Nieman LK, Reincke M, Newell-Price J

    The Journal of clinical endocrinology and metabolism 2021; (106(7)):2114-2123 doi:10.1210/clinem/dgab122.

    PMID: 33675650
  6. 6

    Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study.

    Fleseriu M, Auchus RJ, Huang W, et al.

    Journal of the Endocrine Society 2025; (9(5)):bvaf046 doi:10.1210/jendso/bvaf046.

    PMID: 40226519
  7. 7

    The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.

    Hayashi K, Inoshita N, Kawaguchi K, et al.

    European journal of endocrinology 2016; (174(2)):213-26 doi:10.1530/EJE-15-0689.

    PMID: 26578638
  8. 8

    Medical treatment of functional pituitary adenomas, trials and tribulations.

    Capatina C, Hanzu FA, Hinojosa-Amaya JM, Fleseriu M

    Journal of neuro-oncology 2024; (168(2)):197-213 doi:10.1007/s11060-024-04670-x.

    PMID: 38760632
  9. 9

    Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.

    Tanaka S, Yamamoto M, Morita M, et al.

    Endocrine journal 2019; (66(8)):701-708 doi:10.1507/endocrj.EJ18-0547.

    PMID: 31130573
  10. 10

    [Retrospective analysis to evaluate efficacy and safety of stereotactic radiosurgery in Cushing's disease: 24 cases and a review].

    Roldán Serrano MA, Horcajadas Almansa A, Torres Vela E, et al.

    Neurocirugia (Asturias, Spain) 2016; (27(4)):167-75.

    PMID: 27020252
  11. 11

    Rapid Endocrine Remission After ZAP-X Gyroscopic Radiosurgery for Cushing's Disease: A Case Report.

    Kahvecioglu A, Tekin S, Oguz SH, et al.

    Cureus 2025; (17(11)):e96636 doi:10.7759/cureus.96636.

    PMID: 41393741
  12. 12

    Cabergoline may act as a radioprotective agent in Cushing's disease.

    Thakkar K, Lila A, Sarathi V, et al.

    Clinical endocrinology 2020; (92(1)):55-62 doi:10.1111/cen.14123.

    PMID: 31698511
  13. 13

    Stereotactic radiosurgery for recurrent/residual nonfunctioning pituitary adenoma: a single-arm systematic review and meta-analysis.

    De Nigris Vasconcellos F, Vilela MAD, Garcia Torrico F, et al.

    Acta neurochirurgica 2024; (166(1)):392 doi:10.1007/s00701-024-06296-4.

    PMID: 39356336
  14. 14

    Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors.

    Mantziaris G, Trifiletti DM, Pikis S, Sheehan JP

    Neuro-oncology advances 2025; (7(Suppl 1)):i58-i68 doi:10.1093/noajnl/vdae010.

    PMID: 40718388
  15. 15

    Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

    Nieman LK, Biller BM, Findling JW, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(8)):2807-31 doi:10.1210/jc.2015-1818.

    PMID: 26222757
  16. 16

    Medical therapy in severe hypercortisolism.

    Marques JVO, Boguszewski CL

    Best practice & research. Clinical endocrinology & metabolism 2021; (35(2)):101487 doi:10.1016/j.beem.2021.101487.

    PMID: 33518458
  17. 17

    Cushing's syndrome: Treatment and new therapeutic approaches.

    Ferriere A, Tabarin A

    Best practice & research. Clinical endocrinology & metabolism 2020; (34(2)):101381 doi:10.1016/j.beem.2020.101381.

    PMID: 32035797
  18. 18

    Patient on Multiple Hormone Replacement Therapy for Hip Arthroplasty: How to Omit Noise and Be Focused?

    Patel G, Kahlon S, Ganesh V

    Cureus 2022; (14(8)):e27904 doi:10.7759/cureus.27904.

    PMID: 36120287
  19. 19

    Nelson's Syndrome: An Update.

    Fountas A, Karavitaki N

    Endocrinology and metabolism clinics of North America 2020; (49(3)):413-432 doi:10.1016/j.ecl.2020.05.004.

    PMID: 32741480
  20. 20

    Rapid response of Nelson's syndrome to pasireotide in radiotherapy-naive patient.

    He X, Spencer-Segal JL

    Clinical diabetes and endocrinology 2020; (6(1)):22 doi:10.1186/s40842-020-00110-7.

    PMID: 33292741
  21. 21

    An individualized approach to the management of Cushing disease.

    Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, et al.

    Nature reviews. Endocrinology 2023; (19(10)):581-599 doi:10.1038/s41574-023-00868-7.

    PMID: 37537306
  22. 22

    Long-term morbidity and mortality in patients with Cushing's syndrome.

    Braun LT, Vogel F, Reincke M

    Journal of neuroendocrinology 2022; (34(8)):e13113 doi:10.1111/jne.13113.

    PMID: 35312199

This page explains treatment options for recurrent Cushing disease for educational purposes only. Your endocrinologist and neurosurgeon are the best sources for determining your specific medical management plan.

Get notified when new evidence is published on Cushing disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.